Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.
European Journal of Cancer, July 2023 (191)
Access the article here
Publication